Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 for Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer
NCT07307911Phase 2Completed
- Sponsor
- Damanhour University
- Start
- Nov 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of coenzyme q10 in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Damanhour University. Primary endpoints: Change from Baseline in Serum Nerve Growth Factor Levels at Week 12, Change from Baseline in Serum Neurofilament Light Chain Levels at Week 12 and 2 more. Started Nov 2025; status: completed.
02
Drugs
coenzyme q10
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT07307911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307911.